ARTHEx Biotech's Latest Advances in Gene Modulation
ARTHEx Biotech S.L. is on the forefront of biotechnology innovation, with an exciting announcement regarding their oral presentation at the TIDES Europe Annual Meeting. This event is recognized as one of the leading gatherings for advancements in oligonucleotide technologies, and ARTHEx is thrilled to contribute to this vital dialogue.
About the TIDES Europe Annual Meeting
The TIDES Europe Annual Meeting, scheduled for mid-November, offers a prominent platform for researchers and professionals engaged in the development of oligonucleotide therapies. This year, the gathering will take place in a city well-known for its scientific community and enthusiasm for biomedical advancements.
Presentation Highlights
Dr. Beatriz Llamusí, Chief Scientific Officer and Co-Founder of ARTHEx Biotech, will be presenting groundbreaking research on a novel delivery method to transport oligonucleotide therapies to the central nervous system (CNS). This method utilizes fatty-acid conjugation, a significant technological leap that could unlock numerous opportunities for ARTHEx.
In her presentation titled, "Fatty Acid Conjugation to Enable Oligonucleotide Delivery into the CNS," Dr. Llamusí will share insights into how this innovative approach can potentially transform treatment pathways for various neurological conditions.
Key Aspects of ATX-01
One of the standout projects within ARTHEx is ATX-01, an oleic acid-conjugated antimiR oligonucleotide. It has been specifically designed to inhibit microRNA 23b (miR-23b), which plays a crucial role in regulating MBNL protein expression. This is particularly relevant in patients with myotonic dystrophy type 1 (DM1), a condition characterized by the dysfunction of the MBNL protein due to the upregulation of miR-23b.
Impact on DM1 Patients
ATX-01 shows promise in enhancing MBNL protein expression while significantly reducing the toxic DMPK mRNA levels found in patients suffering from DM1. This corrective action addresses the critical cellular defects associated with this neurological disorder. Presently, ATX-01 is undergoing evaluation in the Phase I-IIa ArthemiR™ trial, marking an important step towards developing effective treatments for DM1.
Regulatory Recognition
ARTHEx has received Orphan Drug Designation for ATX-01 from both US and European regulatory authorities. Additionally, it has been recognized with Rare Pediatric Disease (RPD) Designation from the FDA. These designations underscore the therapeutic potential of ATX-01 in addressing unmet medical needs within the field of neuromuscular disorders.
Company Overview
Headquartered in Valencia, Spain, ARTHEx Biotech is a clinical-stage biotechnology company committed to advancing innovative treatments through the modulation of gene expression. The company aims to develop nucleic acid-based therapies targeting serious diseases, particularly genetically-driven conditions like DM1.
ARTHEx is driven by a mission to improve patient outcomes and as they continue to expand their research capabilities, they remain focused on leveraging their in-house discovery engine to identify new therapeutic opportunities.
Contact Information
For investor and media inquiries, please reach out to:
Frédéric Legros, Executive Chairman and CEO
Phone: +33679495790
Amy Conrad
Phone: +1 858-366-3243
Frequently Asked Questions
What is ATX-01?
ATX-01 is an innovative oligonucleotide designed to target and inhibit microRNA 23b, which is related to myotonic dystrophy type 1 (DM1).
Where will the TIDES Europe Annual Meeting take place?
This year's TIDES Europe Annual Meeting is being held in Hamburg, Germany.
What are the main goals of ARTHEx Biotech?
ARTHEx is focused on developing transformative therapies for neuromuscular disorders through innovative gene expression modulation techniques.
Why is fatty-acid conjugation significant for oligonucleotide therapies?
This technique enhances the delivery of therapeutic agents directly to the CNS, potentially improving efficacy in treating neurological diseases.
What recognitions has ARTHEx received for ATX-01?
ARTHEx has obtained Orphan Drug Designation and Rare Pediatric Disease Designation from relevant regulatory agencies for ATX-01.
